Myriad Genetics' Stock Drops on SCOTUS Decision; Analysts Mixed on Implications | GenomeWeb

NEW YORK (GenomeWeb News) – Shares of Myriad Genetics slid as much as 18 percent today following the decision by the US Supreme Court invalidating the company's patents covering the BRCA1 and BRCA2 genes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.